2.2.0.25falsefalse0212 - Disclosure - Contingencies and commitmentstruefalsefalse1falsefalseUSDfalsefalse1/1/2011 - 3/31/2011
USD ($)
USD ($) / shares
$Jan-01-2011_Mar-31-2011http://www.sec.gov/CIK0000318154duration2011-01-01T00:00:002011-03-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDUSD$2true0amgn_ContingenciesAndCommitmentsAbstractamgnfalsenadurationContingencies and commitments.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringContingencies and commitments.falsefalse3false0us-gaap_CommitmentsAndContingenciesDisclosureTextBlockus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note 12 - us-gaap:CommitmentsAndContingenciesDisclosureTextBlock-->
<div style="font-family: 'Times New Roman',Times,serif">
<div align="left" style="font-size: 10pt; margin-top: 10pt"><b>12. Contingencies and commitments</b>
</div>
<div align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">In the ordinary course of business, we are involved in various legal proceedings and other
matters, including those discussed in this Note, which are complex in nature and have outcomes that
are difficult to predict. We record accruals for such contingencies to the extent that we conclude
that it is probable that a liability will be incurred and the amount of the related loss can be
reasonably estimated. While it is not possible to accurately predict or determine the eventual
outcome of these items, one or more of these items currently pending could have a material adverse
effect on our consolidated results of operations, financial position or cash flows.
</div>
<div align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">Certain of our legal proceedings and other matters are discussed below:
</div>
<div align="left" style="font-size: 10pt; margin-top: 10pt"><i>Roche U.S. International Trade Commission Complaint</i>
</div>
<div align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">On March 11, 2011, the U.S. International Trade Commission issued an order to show cause why
the investigation should not be terminated without a determination of violation or by way of
consent order in view of the resolution of the U.S. District Court for the District of
Massachusetts proceedings. In response, on April 21, 2011, the parties filed a joint response
requesting termination of the investigation on the basis of a proposed Consent Order and
Stipulation.
</div>
<div align="left" style="font-size: 10pt; margin-top: 10pt"><i>Teva Matters</i>
</div>
<div align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%"><i>Sensipar</i><i><sup style="font-size: 85%; vertical-align: text-top">®</sup> Abbreviated New Drug Application Litigation</i>
</div>
<div align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">On April 19, 2011, Teva Pharmaceuticals USA, Inc., Teva Pharmaceutical Industries Ltd. and
Barr Laboratories, Inc. filed an unopposed motion for voluntary dismissal of their appeal. On
April 20, 2011, the U.S. Court of Appeals for the Federal Circuit granted the motion and dismissed
the appeal.
</div>
<div align="left" style="font-size: 10pt; margin-top: 10pt"><i>Simonian v. Amgen Inc.</i>
</div>
<div align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">On April 12, 2011, Amgen and Mr. Simonian reached a settlement and the U.S. District Court for
the Northern District of Illinois dismissed the case with prejudice.
</div>
<div align="left" style="font-size: 10pt; margin-top: 10pt"><i>Average Wholesale Price Litigation</i>
</div>
<div align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">Plaintiffs continue to file for extensions for the final approval hearing of the Track II
settlement due to continued deficiencies in executing notices, and the final approval hearing is
currently scheduled for June 13, 2011.
</div>
<div align="left" style="font-size: 10pt; margin-top: 10pt"><i>Birch v. Sharer, et al.</i>
</div>
<div align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">On February 24, 2011, plaintiff filed a notice of appeal with the California State Appellate
Court. The schedule for briefing the appeal has not yet been set.
</div>
<div align="left" style="font-size: 10pt; margin-top: 10pt"><i>Third-Party Payers Litigation</i>
</div>
<div align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">No appeal was filed with the U.S. Supreme Court by the plaintiffs and the deadline for doing
so has passed.
</div>
<div align="left" style="font-size: 10pt; margin-top: 10pt"><i>Qui Tam Actions</i>
</div>
<div align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">On April 26, 2011, the Massachusetts District Court changed the trial date to be set for the
running trial list starting on October 3, 2011.
</div>
<div align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">On February 11, 2011, the states of New York, Massachusetts, California, Illinois and Indiana,
on behalf of the states of Georgia and New Mexico, and the relator filed reply briefs and oral
argument was heard by the U.S. Court of Appeals for the First Circuit on April 6, 2011. On April
11, 2011, the U.S. District Court for the District of Massachusetts heard summary judgment
arguments on the fourth amended complaint from Amgen, Integrated Nephrology Network and the
relator.
</div>
<!-- Folio -->
<!-- /Folio -->
</div>
<!-- PAGEBREAK -->
<div style="font-family: 'Times New Roman',Times,serif">
<div align="left" style="font-size: 10pt; margin-top: 10pt"><i>Other</i>
</div>
<div align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">In March 2011, the U.S. Attorney’s Office of the Western District of Washington informed Amgen
that the subject matter of its investigation would be transferred to the U.S. Attorney’s Office of
the Eastern District of New York.
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged NotefalsefalsefalsefalsefalseOtherus-types:textBlockItemTypestringIncludes disclosure of commitments and contingencies. This element may be used as a single block of text to encapsulate the entire disclosure including data and tables.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 14
-Paragraph 3
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 9, 10, 11, 12
falsefalse12Contingencies and commitmentsUnKnownUnKnownUnKnownUnKnownfalsetrue